BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-313 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-313\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07673120-11126@assetmemo.bio
DTSTAMP:20261121T005401Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:ABBV-313: Phase 1 readout est. (NCT07673120)
DESCRIPTION:ABBV-313\, phase 1.\nStudy: A Study to Assess Safety\, Tolerabi
 lity\, and How Single and Multiple Injections or Infusions of ABBV-313 Aff
 ects the Body of Adult Participants\nEstimated primary completion: Februar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-313#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07673120
URL:https://assetmemo.bio/drug/abbv-313#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
